AMLX

Amylyx Pharmaceuticals, Inc.

BS score 16.8LOWPHASE3 · mkt cap $1.91B · rev ttm $0

drug hypothesis

AMX0035 modulates Not disclosed in provided SEC filing materials to treat Amyotrophic Lateral Sclerosis (ALS).

moa:Not disclosed in provided SEC filing materials

score breakdown

trial design0

base rate disconnect12

language red flags60

composite16.8

valuation analysis

market cap$1.91B

revenue ttm$0

phasePHASE3

historical base rate30%

disconnect ratio0.4x

meta

cik0001658551

first discovered2026-04-09

last updated2026-04-10

statusACTIVE

llm model—

extracted at2026-04-10

trial design

Phase III, randomized, quadruple-blind, placebo-controlled trial enrolling 664 participants with ALS

primary endpoint:Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Slope Change at 48 weeks

claimed differentiation

Not disclosed in provided SEC filing materials

language red flags

SEC filing content extremely limited (only section number '3' provided) - unable to assess company language, claims, or risk disclosures
No mechanism of action, target, or preclinical evidence provided in filing materials
Cannot assess for hedging, vague claims, or unsubstantiated differentiation without business section text

company-stated risks

upcoming catalysts